Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients.

Teruhiko HiguchiJun IshigookaMasaomi IyoChin-Bin YehEsther Gunaseli EbenezerKuei Yu LiangJung Sik LeeSang Yeol LeeShih Ku LinBo-Hyun YoonMasatoshi NakamuraKatsuhiko HagiTakayuki Sato

Published in: Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists (2019)

In the ITT (but not the mITT) population, treatment with lurasidone was associated with significant improvement in the PANSS total score in patients with schizophrenia. Lurasidone was generally well tolerated with minimal impact on weight and metabolic parameters.

Keyphrases

end stage renal disease
ejection fraction
bipolar disorder
body mass index
prognostic factors
combination therapy
patient reported outcomes
body weight